Citigroup Inc Outlook Therapeutics, Inc. Transaction History

Citigroup Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.22 - $0.66 $5,277 - $15,831	23,987 Added 8300.0%	24,276 $9,000
Q3 2023 Nov 09, 2023	SELL	$0.2 - $1.78 $9,181 - $81,712	-45,906 Reduced 99.37%	289 $0
Q2 2023 Aug 10, 2023	BUY	$1.02 - $1.89 $47,118 - $87,308	46,195 New	46,195 $80,000
Q4 2022 Feb 09, 2023	SELL	$0.87 - $1.33 $864 - $1,322	-994 Reduced 55.47%	798 $0
Q3 2022 Nov 10, 2022	SELL	$1.02 - $1.26 $6,082 - $7,513	-5,963 Reduced 76.89%	1,792 $2,000
Q2 2022 Aug 10, 2022	BUY	$0.91 - $2.01 $3,329 - $7,354	3,659 Added 89.33%	7,755 $8,000
Q1 2022 May 12, 2022	SELL	$1.22 - $2.03 $22,993 - $38,259	-18,847 Reduced 82.15%	4,096 $7,000
Q4 2021 Feb 10, 2022	BUY	$1.27 - $2.23 $14,602 - $25,640	11,498 Added 100.46%	22,943 $31,000
Q3 2021 Nov 10, 2021	BUY	$2.12 - $2.76 $24,263 - $31,588	11,445 New	11,445 $25,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.18B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.